GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: European Journal of Haematology, Wiley, Vol. 111, No. 2 ( 2023-08), p. 229-239
    Abstract: Initial responses to coronavirus disease 2019 vaccination are impaired in patients with hematological malignancies. We investigated immune responses after three or four doses of BNT162b2 in patients with myeloid and lymphoid malignancies compared to controls, and identified risk factors for humoral and cellular nonresponse 1 year after first vaccination. Methods In 407 hematological patients (45 myeloid, 362 lymphoid) and 98 matched controls, we measured immunoglobulin G (IgG) and neutralizing antibodies specific for the receptor‐binding domain of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) at baseline, 3 weeks, 2, 6, and 12 months, and interferon‐γ release at 12 months. Results In patients with lymphoid malignancies, SARS‐CoV‐2 receptor‐binding domain IgG concentration and mean neutralizing capacity was lower than in controls at all time points. A diagnosis of chronic lymphocytic B‐cell leukemia (CLL) or lymphoma was associated with humoral nonresponse at 12 months compared to having multiple myeloma/amyloidosis ( p   〈  .001 and p  = .013). Compared to controls, patients with lymphoid malignancies had increased risk of cellular nonresponse. A lymphoma diagnosis was associated with lower risk of cellular nonresponse compared to patients with multiple myeloma/amyloidosis, while patients with CLL had comparable response rates to patients with multiple myeloma/amyloidosis ( p  = .037 and p  = .280). Conclusions In conclusion, long‐term humoral and cellular immune responses to BNT162b2 were impaired in patients with lymphoid malignancies.
    Type of Medium: Online Resource
    ISSN: 0902-4441 , 1600-0609
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2023
    detail.hit.zdb_id: 2027114-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    Wiley ; 2020
    In:  WIREs Energy and Environment Vol. 9, No. 1 ( 2020-01)
    In: WIREs Energy and Environment, Wiley, Vol. 9, No. 1 ( 2020-01)
    Abstract: This article surveys the politics of plastics through a reading and analysis of more than 180 scientific articles in the fields of environmental science and environmental studies. Despite the many benefits of plastics, the global plastic system is increasingly being recognized as the source of severe environmental problems. Rather than orient the investigation around specific venues, levels, or architectures of governance, our survey first follows plastic through its life cycle, and then considers the major categories of plastic objects addressed in the current literature, and the different approaches taken to each category. The politics of plastics is a growing field of inquiry, with the most rapid expansion in the areas of marine pollution and microplastics. Our consideration of plastic flows reveals increasing politicization towards the latter end of the life cycle, that is, plastic as waste and pollution. Turning to plastic objects, we observe different forms of mobilization, and varying connections between flows and objects, which allow for multiple interpretations of what is at stake. In the closing section, we consider two recent trends in the plastic governance discussion that take a more holistic view of the plastic crisis: attempts to construct (a) a circular plastics economy and (b) global plastics conventions or treaties. We end the paper by highlighting the need for studies to further investigate the norms and practices that maintain the role of plastics in society, as well as the political and economic arrangements that secure its overabundance and low price. This article is categorized under: Energy Policy and Planning 〉 Economics and Policy Fossil Fuels 〉 Science and Materials Fossil Fuels 〉 Climate and Environment
    Type of Medium: Online Resource
    ISSN: 2041-8396 , 2041-840X
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2020
    detail.hit.zdb_id: 2681570-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    Wiley ; 2022
    In:  International Journal of Dermatology Vol. 61, No. 2 ( 2022-02), p. 148-157
    In: International Journal of Dermatology, Wiley, Vol. 61, No. 2 ( 2022-02), p. 148-157
    Abstract: Hyperhidrosis is excessive sweating that is uncontrollable and occurring regardless of temperature. Quality of life is significantly impaired, and psychiatric comorbidity is common. The objective of the study is to undertake a systematic review of research in the last 5 years regarding hyperhidrosis. Five databases were searched from July 2015 to July 2020 for all research on hyperhidrosis. High‐quality research articles were sought for progress in diagnosis, etiology and epidemiology, and use of patient reported outcomes (PROs) as well as randomized clinical trials (RCTs) on any treatment intervention. Outcomes of interest were disease severity, sweat rate, quality of life, patient satisfaction, and adverse events. Trial quality was assessed by the Cochrane risk‐of‐bias tool. A narrative synthesis was presented. Twenty‐nine papers were included in the review: 13 investigational articles, 10 RCTs, three cohort studies, and three reviews. The studies varied in terms of quality, population, intervention, and methods of outcome assessment. The majority were very small studies, and most RCTs were at high risk of bias. Few studies on diagnosis, epidemiology, and etiology were of sufficient quality to be presented. The interventions discussed were iontophoresis, botulinum toxin, anticholinergic medication, curettage, and energy‐based technologies. Progress in the diagnostics and etiology of hyperhidrosis is limited with the same being true for treatment. In a 5‐year‐old systematic review, it was concluded that there was moderate‐quality evidence to support the use of botulinum toxin for axillary hyperhidrosis. It was advocated to conduct a trial comparing BTX and iontophoresis for palmar hyperhidrosis. Unfortunately, this has not yet been performed. Hyperhidrosis is still as underserved and under‐studied as before.
    Type of Medium: Online Resource
    ISSN: 0011-9059 , 1365-4632
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2022
    detail.hit.zdb_id: 2020365-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Alzheimer's & Dementia, Wiley, Vol. 19, No. S3 ( 2023-06)
    Abstract: Sleep dysfunction is common in neurodegenerative disorders, however, its neural correlates, remain poorly characterized in genetic frontotemporal dementia (FTD). Atrophy in two hypothalamic nuclei, the suprachiasmatic nucleus and the lateral hypothalamic area, important for sleep regulation, may be related to this dysfunction. Thus, we examined changes in cerebral and hypothalamic structure across the lifespan in genetic FTD and their relations to measures of sleep dysfunction. Method Data was retrieved from the Genetic Frontotemporal Dementia Initiative (GENFI). T1‐weighted structural MRI images and scores on the Cambridge Behavioural Inventory‐Revised (CBI‐R) sleep subscale were obtained from subjects with mutations causative of FTD (n = 491, scan number = 1029) and healthy controls (n = 321, scan number = 739). MRI images were processed for cortical thickness using CIVET 2.1 and hypothalamic volumes using a deep learning segmentation algorithm (Billot et al., NeuroImage 2020). Using linear mixed‐effects models, we examined changes in sleep dysfunction, vertex‐wise differences in cortical thickness, and volumetric changes in hypothalamic regions in mutation carriers compared to controls. Further, using linear mixed‐effects models, we examined associations between cortical and hypothalamic atrophy and changes in the CBI‐R sleep subscale while controlling for age, sex, scanning site, and disease severity based on the MMSE. Result Mutation carriers showed greater sleep dysfunction across the lifespan, and this increased closer to the predicted onset of symptoms, compared to controls (p 〈 0.01), with MAPT carriers having greater dysfunction overall (figure 1). All mutation carriers showed patterns of cortical thinning (figure 2) commensurate with the literature (p 〈 0.05, FDR corrected). Further, cortical thinning in frontal and parietal regions were associated with greater sleep disturbance in C9orf72 and GRN mutation carriers (p 〈 0.05, FDR corrected) (figure 3). Lastly, MAPT mutation carriers showed consistently significant hypothalamic volume loss across the lifespan (figure 4) (p 〈 0.01) and reduced hypothalamic volumes were related to increased sleep dysfunction (p 〈 0.05) (Figure 5). Conclusion These findings suggest that while cortical thinning in C9orf72 and GRN carriers non‐specifically correlate with increased sleep dysfunction, the increased sleep dysfunction observed in MAPT carriers may be attributable to increased hypothalamic atrophy.
    Type of Medium: Online Resource
    ISSN: 1552-5260 , 1552-5279
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2023
    detail.hit.zdb_id: 2201940-6
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Human Brain Mapping, Wiley, Vol. 44, No. 7 ( 2023-05), p. 2684-2700
    Abstract: Recent studies have reported early cerebellar and subcortical impact in the disease progression of genetic frontotemporal dementia (FTD) due to microtubule‐associated protein tau ( MAPT ), progranulin ( GRN ) and chromosome 9 open reading frame 72 ( C9orf72 ). However, the cerebello‐subcortical circuitry in FTD has been understudied despite its essential role in cognition and behaviors related to FTD symptomatology. The present study aims to investigate the association between cerebellar and subcortical atrophy, and neuropsychiatric symptoms across genetic mutations. Our study included 983 participants from the Genetic Frontotemporal dementia Initiative including mutation carriers and noncarrier first‐degree relatives of known symptomatic carriers. Voxel‐wise analysis of the thalamus, striatum, globus pallidus, amygdala, and the cerebellum was performed, and partial least squares analyses (PLS) were used to link morphometry and behavior. In presymptomatic C9orf72 expansion carriers, thalamic atrophy was found compared to noncarriers, suggesting the importance of this structure in FTD prodromes. PLS analyses demonstrated that the cerebello‐subcortical circuitry is related to neuropsychiatric symptoms, with significant overlap in brain/behavior patterns, but also specificity for each genetic mutation group. The largest differences were in the cerebellar atrophy (larger extent in C9orf72 expansion group) and more prominent amygdalar volume reduction in the MAPT group. Brain scores in the C9orf72 expansion carriers and MAPT carriers demonstrated covariation patterns concordant with atrophy patterns detectable up to 20 years before expected symptom onset. Overall, these results demonstrated the important role of the subcortical structures in genetic FTD symptom expression, particularly the cerebellum in C9orf72 and the amygdala in MAPT  carriers.
    Type of Medium: Online Resource
    ISSN: 1065-9471 , 1097-0193
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2023
    detail.hit.zdb_id: 1492703-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Research Synthesis Methods, Wiley
    Abstract: The objective of this meta‐epidemiological study was to explore the impact of attrition rates on treatment effect estimates in randomised trials of chronic inflammatory diseases (CID) treated with biological and targeted synthetic disease‐modifying drugs. We sampled trials from Cochrane reviews. Attrition rates and primary endpoint results were retrieved from trial publications; Odds ratios (ORs) were calculated from the odds of withdrawing in the experimental intervention compared to the control comparison groups (i.e., differential attrition), as well as the odds of achieving a clinical response (i.e., the trial outcome). Trials were combined using random effects restricted maximum likelihood meta‐regression models and associations between estimates of treatment effects and attrition rates were analysed. From 37 meta‐analyses, 179 trials were included, and 163 were analysed (301 randomised comparisons; n = 62,220 patients). Overall, the odds of withdrawal were lower in the experimental compared to control groups (random effects summary OR = 0.45, 95% CI, 0.41–0.50). The corresponding overall treatment effects were large (random effects summary OR = 4.43, 95% CI 3.92–4.99) with considerable heterogeneity across interventions and clinical specialties ( I 2 = 85.7%). The ORs estimating treatment effect showed larger treatment benefits when the differential attrition was more prominent with more attrition in the control group (OR = 0.73, 95% CI 0.55–0.96). Higher attrition rates from the control arm are associated with larger estimated benefits of treatments with biological or targeted synthetic disease‐modifying drugs in CID trials; differential attrition may affect estimates of treatment benefit in randomised trials.
    Type of Medium: Online Resource
    ISSN: 1759-2879 , 1759-2887
    Language: English
    Publisher: Wiley
    Publication Date: 2024
    detail.hit.zdb_id: 2548499-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: ChemBioChem, Wiley, Vol. 24, No. 24 ( 2023-12-14)
    Type of Medium: Online Resource
    ISSN: 1439-4227 , 1439-7633
    URL: Issue
    RVK:
    Language: English
    Publisher: Wiley
    Publication Date: 2023
    detail.hit.zdb_id: 2020469-3
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    In: European Journal of Heart Failure, Wiley, Vol. 22, No. 9 ( 2020-09), p. 1628-1637
    Abstract: The present study tested the hypothesis that metformin treatment may increase myocardial efficiency (stroke work/myocardial oxygen consumption) in insulin‐resistant patients with heart failure and reduced ejection fraction (HFrEF) without diabetes. Methods and results Thirty‐six HFrEF patients (ejection fraction 37 ± 8%; median age 66 years) were randomised to metformin ( n = 19) or placebo ( n = 17) for 3 months in addition to standard heart failure therapy. The primary endpoint was change in myocardial efficiency expressed as the work metabolic index (WMI), assessed by 11 C‐acetate positron emission tomography and transthoracic echocardiography. Compared with placebo, metformin treatment (1450 ± 550 mg/day) increased WMI [absolute mean difference, 1.0 mmHg·mL·m ‐2 ·10 6 ; 95% confidence interval (CI) 0.1 to 1.8; P = 0.03], equivalent to a 20% relative efficiency increase. Patients with above‐median plasma metformin levels displayed greater WMI increase (25% vs. –4%; P = 0.02). Metformin reduced myocardial oxygen consumption (–1.6 mL O 2 ·100 g ‐1 ·min ‐1 ; P = 0.014). Cardiac stroke work was preserved (–2 J; 95% CI –11 to 7; P = 0.69). Metformin reduced body weight (–2.2 kg; 95% CI –3.6 to –0.8; P = 0.003) and glycated haemoglobin levels (–0.2%; 95% CI –0.3 to 0.0; P = 0.02). Changes in resting and exercise ejection fraction, global longitudinal strain, and exercise capacity did not differ between groups. Conclusion Metformin treatment in non‐diabetic HFrEF patients improved myocardial efficiency by reducing myocardial oxygen consumption. Measurement of circulating metformin levels differentiated responders from non‐responders. These energy‐sparing effects of metformin encourage further large‐scale investigations in heart failure patients without diabetes.
    Type of Medium: Online Resource
    ISSN: 1388-9842 , 1879-0844
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2020
    detail.hit.zdb_id: 1500332-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    In: Journal of Internal Medicine, Wiley, Vol. 293, No. 6 ( 2023-06), p. 763-781
    Abstract: Factors influencing SARS‐CoV‐2 antibody dynamics, transmission, waning and long COVID‐19 symptomatology are still not fully understood. Methods In the Danish section of the Novo Nordisk Group, we performed a prospective seroepidemiological study during the first and second waves of the COVID‐19 pandemic. All employees and their household members ( 〉 18 years) were invited to participate in a baseline (June–August 2020), 6‐month follow‐up (December 2020–January 2021), and 12‐month follow‐up (August 2021) sampling. In total, 18,614 accepted and provided at least one blood sample and completed a questionnaire regarding socioeconomic background, health status, previous SARS‐CoV‐2 infection, and persistent symptoms. Total antibody and specific IgM, IgG and IgA levels against recombinant receptor binding domain were tested. Results At baseline, the SARS‐CoV‐2‐antibody seroprevalence was 3.9%. At 6‐month follow‐up, the seroprevalence was 9.1%, while at 12‐month follow‐up, the seroprevalence was 94.4% (after the vaccine roll‐out). Male sex and younger age (18–40 years) were significant risk factors for seropositivity. From baseline to the 6‐month sampling, we observed a substantial waning of IgM, IgG and IgA levels ( p   〈  0.001), regardless of age, sex and initial antibody level. An increased antibody level was found in individuals infected prior to vaccination compared to vaccinated infection naïves ( p   〈  0.0001). Approximately a third of the seropositive individuals reported one or more persistent COVID‐19 symptoms, with anosmia and/or ageusia (17.5%) and fatigue (15.3%) being the most prevalent. Conclusion The study provides a comprehensive insight into SARS‐CoV‐2 antibody seroprevalence following infection and vaccination, waning, persistent COVID‐19 symptomatology and risk factors for seropositivity in large working environments.
    Type of Medium: Online Resource
    ISSN: 0954-6820 , 1365-2796
    URL: Issue
    RVK:
    Language: English
    Publisher: Wiley
    Publication Date: 2023
    detail.hit.zdb_id: 2006883-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    Online Resource
    Online Resource
    Wiley ; 2022
    In:  Skin Health and Disease Vol. 2, No. 4 ( 2022-12)
    In: Skin Health and Disease, Wiley, Vol. 2, No. 4 ( 2022-12)
    Abstract: It is widely acknowledged that negative body image perception is linked to anxiety, depression, and body dysmorphic disorder. However, there is no gold standard, body image related patient reported outcome measure in use, specific for dermatologic disease, despite evidence to suggest a high prevalence of mental health problems relating to body image in this group of patients. Aim The aim of this study was to perform a review of body image Patient Reported Outcome Measures (PROMs) used in dermatology and to evaluate their effectiveness. Methods Searches were performed in the major databases. Two investigators independently performed full text evaluation by applying an established checklist to evaluate the conceptual model, content validity, reliability, construct validity, scoring and interpretability and respondent burden. Results Six different PROMs were identified of which only one was fully validated. There was a significant lack of patient involvement in the development of PROMs in this context. Conclusions We therefore encourage further research in this field to improve the quality of evidence to better understand the relationship between mental health and dermatologic disease.
    Type of Medium: Online Resource
    ISSN: 2690-442X , 2690-442X
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2022
    detail.hit.zdb_id: 3056511-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...